In Q42017, ISR surveyed outsourcers of biologic API and outsourcers of biologic drug product to ask whether their company uses a preferred providers list of contract manufacturers for outsourced biologic manufacturing. The data show use of preferred providers is more common for biologic drug product manufacturing than biologic API manufacturing (61% vs. 47%). To learn more, follow the links to the Biologic API and the Biologic Drug Product report previews.

Originally published at Bioprocess Online.

View File